GB2473575B - Diagnosis of autism - Google Patents

Diagnosis of autism

Info

Publication number
GB2473575B
GB2473575B GB1021794.1A GB201021794A GB2473575B GB 2473575 B GB2473575 B GB 2473575B GB 201021794 A GB201021794 A GB 201021794A GB 2473575 B GB2473575 B GB 2473575B
Authority
GB
United Kingdom
Prior art keywords
autism
diagnosis
behavioural
eif4e
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1021794.1A
Other versions
GB2473575A (en
GB201021794D0 (en
Inventor
Zosia Meidzybrodzka
David St Clair
Berndt Muller
Milu Neves-Pereira
Doreen Massie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Grampian Health Board
Original Assignee
University of Aberdeen
Grampian Health Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen, Grampian Health Board filed Critical University of Aberdeen
Publication of GB201021794D0 publication Critical patent/GB201021794D0/en
Publication of GB2473575A publication Critical patent/GB2473575A/en
Application granted granted Critical
Publication of GB2473575B publication Critical patent/GB2473575B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention concerns the identification of a novel drug target for use in the treatment of behavioural dis order, hi particular, the invention provides compounds capable of modulating the expression, function and/or activity of eIF4E, for use in treating a behavioural disorder as well as methods of identifying the same.
GB1021794.1A 2008-05-30 2009-05-29 Diagnosis of autism Expired - Fee Related GB2473575B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0809821.2A GB0809821D0 (en) 2008-05-30 2008-05-30 Treatment and diagnosis of behavioural disorders
PCT/GB2009/001367 WO2009144480A1 (en) 2008-05-30 2009-05-29 Treatment and diagnosis of behavioural disorders

Publications (3)

Publication Number Publication Date
GB201021794D0 GB201021794D0 (en) 2011-02-02
GB2473575A GB2473575A (en) 2011-03-16
GB2473575B true GB2473575B (en) 2013-02-20

Family

ID=39637839

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0809821.2A Ceased GB0809821D0 (en) 2008-05-30 2008-05-30 Treatment and diagnosis of behavioural disorders
GB1021794.1A Expired - Fee Related GB2473575B (en) 2008-05-30 2009-05-29 Diagnosis of autism

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0809821.2A Ceased GB0809821D0 (en) 2008-05-30 2008-05-30 Treatment and diagnosis of behavioural disorders

Country Status (2)

Country Link
GB (2) GB0809821D0 (en)
WO (1) WO2009144480A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503646A (en) 2009-09-08 2013-02-04 ラボラトリー コーポレイション オブ アメリカ ホールディングス Compositions and methods for diagnosing autism spectrum disorders
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
EP3440100A4 (en) 2016-04-04 2020-01-22 University of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
CA3060250A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regulation of ran protein translation by pkr and eif2a-p pathways
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
US20240052004A1 (en) * 2019-10-04 2024-02-15 Yale University Targeting cap-dependent translation to reduce seizures in mtor disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094755A2 (en) * 2005-02-04 2007-08-23 Massachusetts Institute Of Technology Compositions and methods for modulating cognitive function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094755A2 (en) * 2005-02-04 2007-08-23 Massachusetts Institute Of Technology Compositions and methods for modulating cognitive function

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochem. J., Vol.356, 2001, Saghir, A. N. et al., "Modifications of eukaryotic initiation factor...", pp.557-566 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 338, 2005 Ogawa et al, "A functional link between disrupted-In-Schizophrenia 1 and the eukaryotic translation initiation factor 3" , page 771-776 *
JOURNAL OF MEDICAL GENETICS, Vol. 45, 2008, Z Miedzybrodzka et al, "Disruption of the EIF4E Gene in Non-Syndromic Autism" pages S16 *
Mol. Cell. Biol., Vol.9, 1989, Altmann, M. et al., "Translation in Saccharomyces...", pp.4467-4472 *
NATURE GENETICS, Vol. 34, 2003, S Jamain et al, "Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism", pages 27-29 *
NEUROSCIENCE LETTERS, Vol. 434, 2008, Yoon et al, "The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex", pages 23-28 *

Also Published As

Publication number Publication date
WO2009144480A1 (en) 2009-12-03
GB0809821D0 (en) 2008-07-09
GB2473575A (en) 2011-03-16
GB201021794D0 (en) 2011-02-02

Similar Documents

Publication Publication Date Title
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
UA98629C2 (en) Compounds and methods for kinase modulation
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
PH12015500730A1 (en) Inhibitors of histone demethylases
UA107667C2 (en) Medical compounds stimulating activity of pyruvate kinase m2, compositions on their basis and use in the treatment of cancer
GB2473575B (en) Diagnosis of autism
AU2011328009A8 (en) Compounds and methods for treating pain
TW200714283A (en) Method and composition for treating peripheral vascular diseases
EP4295912A3 (en) Compounds and methods for kinase modulation, and indications therefor
MX2015006939A (en) Treatment of cancer with heterocyclic inhibitors of glutaminase.
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
MX2012003770A (en) Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products.
EA201201650A1 (en) HUMAN BINDING MOLECULES THAT HAVE KILLING ACTIVITY AGAINST STAFILOCCUS AND THEIR APPLICATION
MX2012000034A (en) Methods for treating or preventing fatigue.
WO2010034015A3 (en) Modulating the alternative complement pathway
UY33276A (en) AMINO-OXAZINES AND AMINO-DIHYDROTIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
BRPI0909447A2 (en) Composition, methods for treating a human or animal subject in need of such treatment and for killing or inhibiting the growth of susceptible microorganisms, and use of a composition.
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MY155340A (en) Use of cathepsin c
MX2010000956A (en) Compounds which inhibit beta-secretase activity and methods of use thereof.
BRPI0920170A2 (en) methods for decreasing the amount of small, dense ldl particles and blood triglyceride and ldl levels in a human, and for identifying a candidate individual for treatment with a compound or salt, prodrug or isomer thereof, compound or salt, prodrug or isomer thereof, and method.
WO2011097522A3 (en) Combination methods for treatment of disease
MX2009009693A (en) Methods of activating irs-1 and akt.
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20150529